Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Xilio Therapeutics (NASDAQ:XLO) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Xilio Therapeutics Stock Down 4.1%

Shares of XLO stock opened at $8.32 on Friday. The firm has a 50 day moving average of $7.96 and a 200-day moving average of $9.56. The company has a market cap of $48.09 million, a price-to-earnings ratio of -1.51 and a beta of -0.05. Xilio Therapeutics has a 52 week low of $6.47 and a 52 week high of $16.52.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Monday, March 23rd. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.83. The company had revenue of $13.69 million for the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics had a negative net margin of 80.05% and a negative return on equity of 393.01%. Analysts anticipate that Xilio Therapeutics will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Xilio Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. acquired a new position in shares of Xilio Therapeutics during the fourth quarter worth approximately $3,787,000. Bain Capital Life Sciences Investors LLC increased its stake in Xilio Therapeutics by 61.4% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock valued at $4,720,000 after purchasing an additional 2,805,869 shares in the last quarter. Empery Asset Management LP bought a new stake in Xilio Therapeutics during the 4th quarter valued at $757,000. Ghisallo Capital Management LLC acquired a new position in Xilio Therapeutics during the fourth quarter worth $713,000. Finally, Velan Capital Investment Management LP acquired a new position in Xilio Therapeutics during the fourth quarter worth $109,000. Institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.